Morepen Laboratories Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Morepen Laboratories has got clearance from Subject Expert Committee (SEC) of Central Drugs Standard Control Organization (CDSCO) to conduct Bioequivalence (BE) studies for Resmetirom 60 mg, 80 mg and 100 mg tablets as per the protocol submitted. This will be followed by clinical trials as per approved protocols.

Resmetirom is a highly promising therapy under development for non-alcoholic steatohepatitis ('NASH'), a serious form of non-alcoholic fatty liver disease (NAFLD) characterized by inflammation, liver damage, and fat accumulation in the liver, potentially leading to scarring (fibrosis), cirrhosis, and even liver cancer. It is often associated with obesity, metabolic syndrome, and type 2 diabetes, and while it can be a silent disease in the early stages, it can progress to severe liver damage if left untreated.

As one of the first Indian companies to foray into this therapeutic area, Morepen is strategically positioned to serve both domestic and international markets and is also evaluating out-licencing opportunities with potential marketing partners.

Powered by Capital Market - Live News

Morepen Laboratories announced the launch of four new products?Ticapen, UdoFix, LycoMore, Acifix in the month of April 2025 to cater the domestic market in addition to Empamore launched last month continuing.

This strategic expansion reinforces Morepen's commitment to scaling its finished dosages business while continuing to invest in cutting-edge R&D that powers a robust pipeline of differentiated, high quality medicines. Importantly, all APIs used in these products are manufactured in-house by Morepen at its world-class, USFDA-approved plants, ensuring consistent quality and supply chain control.

Powered by Capital Market - Live News

The move is aimed at strengthening Morepen?s connect with doctors, pharmacies, patients, and healthcare professionals nationwide. It marks a bold step in scaling up the company?s formulations business, which currently stands at around Rs 325 crore. Morepen has set its sights on building a Rs 1,000 crore finished dosages segment within the next five years.

To achieve this, the company plans aggressive expansion of its medical representative network and deeper market penetration across both urban and rural India. A key driver of this growth will be its pipeline of competitively priced new products already in production.

The Indian pharmaceutical market, projected to reach $130 billion by 2030 with an annual growth rate of 8.2%, positions India as the emerging pharmacy of the world?offering a strong runway for players like Morepen.

Morepen Laboratories' operations span APIs, medical devices, and finished formulations. The company is a global exporter of six major APIs, including Loratadine, Montelukast, Desloratadine, Atorvastatin, and Fexofenadine. In the medical devices segment, Morepen has installed over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips, supporting its expansion into tier-2 and tier-3 cities.

The company's consolidated net profit fell 16.6% to Rs 26.69 crore while revenue from operations rose 1.9% to Rs 452.78 crore in Q3 December 2024 over Q3 December 2023.

Powered by Capital Market - Live News

Morepen Laboratories announced the launch of four new products?Ticapen, UdoFix, LycoMore, Acifix in the month of April 2025 to cater the domestic market in addition to Empamore launched last month continuing.

This strategic expansion reinforces Morepen's commitment to scaling its finished dosages business while continuing to invest in cutting-edge R&D that powers a robust pipeline of differentiated, high quality medicines. Importantly, all APIs used in these products are manufactured in-house by Morepen at its world-class, USFDA-approved plants, ensuring consistent quality and supply chain control.

Powered by Capital Market - Live News

The move is aimed at strengthening Morepen?s connect with doctors, pharmacies, patients, and healthcare professionals nationwide. It marks a bold step in scaling up the company?s formulations business, which currently stands at around Rs 325 crore. Morepen has set its sights on building a Rs 1,000 crore finished dosages segment within the next five years.

To achieve this, the company plans aggressive expansion of its medical representative network and deeper market penetration across both urban and rural India. A key driver of this growth will be its pipeline of competitively priced new products already in production.

The Indian pharmaceutical market, projected to reach $130 billion by 2030 with an annual growth rate of 8.2%, positions India as the emerging pharmacy of the world?offering a strong runway for players like Morepen.

Morepen Laboratories' operations span APIs, medical devices, and finished formulations. The company is a global exporter of six major APIs, including Loratadine, Montelukast, Desloratadine, Atorvastatin, and Fexofenadine. In the medical devices segment, Morepen has installed over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips, supporting its expansion into tier-2 and tier-3 cities.

The company's consolidated net profit fell 16.6% to Rs 26.69 crore while revenue from operations rose 1.9% to Rs 452.78 crore in Q3 December 2024 over Q3 December 2023.

Powered by Capital Market - Live News

Morepen Laboratories today announced a bold expansion plan aimed at deepening its connect with doctors, patients, pharmacies, and healthcare professionals across the country. As part of this strategic initiative, the company will add more than 1,000 professionals to its salesforce over the next three years, with over 200 team members expected to join in FY26 alone.

This expansion represents a pivotal moment in Morepen's journey as we sharpen our focus on the expanding domes c finished dosage market, said Sushil Suri, Chairman and Managing Director of Morepen Laboratories. With the leadership in our high value APIs, this significant increase in our salesforce and enhanced reach to doctors, pharmacies, and patients, we are se ng the stage for getting a bigger pie in the Indian pharmaceutical market valued at ₹2.38 lakh crore, yielding higher gross margins and be er returns for stakeholders in the long run.?

Powered by Capital Market - Live News

Morepen Laboratories has got clearance from Subject Expert Committee (SEC) of Central Drugs Standard Control Organization (CDSCO) to conduct Bioequivalence (BE) studies for Resmetirom 60 mg, 80 mg and 100 mg tablets as per the protocol submitted. This will be followed by clinical trials as per approved protocols.

Resmetirom is a highly promising therapy under development for non-alcoholic steatohepatitis ('NASH'), a serious form of non-alcoholic fatty liver disease (NAFLD) characterized by inflammation, liver damage, and fat accumulation in the liver, potentially leading to scarring (fibrosis), cirrhosis, and even liver cancer. It is often associated with obesity, metabolic syndrome, and type 2 diabetes, and while it can be a silent disease in the early stages, it can progress to severe liver damage if left untreated.

As one of the first Indian companies to foray into this therapeutic area, Morepen is strategically positioned to serve both domestic and international markets and is also evaluating out-licencing opportunities with potential marketing partners.

Powered by Capital Market - Live News

Morepen Laboratories announced the launch of four new products?Ticapen, UdoFix, LycoMore, Acifix in the month of April 2025 to cater the domestic market in addition to Empamore launched last month continuing.

This strategic expansion reinforces Morepen's commitment to scaling its finished dosages business while continuing to invest in cutting-edge R&D that powers a robust pipeline of differentiated, high quality medicines. Importantly, all APIs used in these products are manufactured in-house by Morepen at its world-class, USFDA-approved plants, ensuring consistent quality and supply chain control.

Powered by Capital Market - Live News

The move is aimed at strengthening Morepen?s connect with doctors, pharmacies, patients, and healthcare professionals nationwide. It marks a bold step in scaling up the company?s formulations business, which currently stands at around Rs 325 crore. Morepen has set its sights on building a Rs 1,000 crore finished dosages segment within the next five years.

To achieve this, the company plans aggressive expansion of its medical representative network and deeper market penetration across both urban and rural India. A key driver of this growth will be its pipeline of competitively priced new products already in production.

The Indian pharmaceutical market, projected to reach $130 billion by 2030 with an annual growth rate of 8.2%, positions India as the emerging pharmacy of the world?offering a strong runway for players like Morepen.

Morepen Laboratories' operations span APIs, medical devices, and finished formulations. The company is a global exporter of six major APIs, including Loratadine, Montelukast, Desloratadine, Atorvastatin, and Fexofenadine. In the medical devices segment, Morepen has installed over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips, supporting its expansion into tier-2 and tier-3 cities.

The company's consolidated net profit fell 16.6% to Rs 26.69 crore while revenue from operations rose 1.9% to Rs 452.78 crore in Q3 December 2024 over Q3 December 2023.

Powered by Capital Market - Live News

Morepen Laboratories announced the launch of four new products?Ticapen, UdoFix, LycoMore, Acifix in the month of April 2025 to cater the domestic market in addition to Empamore launched last month continuing.

This strategic expansion reinforces Morepen's commitment to scaling its finished dosages business while continuing to invest in cutting-edge R&D that powers a robust pipeline of differentiated, high quality medicines. Importantly, all APIs used in these products are manufactured in-house by Morepen at its world-class, USFDA-approved plants, ensuring consistent quality and supply chain control.

Powered by Capital Market - Live News

The move is aimed at strengthening Morepen?s connect with doctors, pharmacies, patients, and healthcare professionals nationwide. It marks a bold step in scaling up the company?s formulations business, which currently stands at around Rs 325 crore. Morepen has set its sights on building a Rs 1,000 crore finished dosages segment within the next five years.

To achieve this, the company plans aggressive expansion of its medical representative network and deeper market penetration across both urban and rural India. A key driver of this growth will be its pipeline of competitively priced new products already in production.

The Indian pharmaceutical market, projected to reach $130 billion by 2030 with an annual growth rate of 8.2%, positions India as the emerging pharmacy of the world?offering a strong runway for players like Morepen.

Morepen Laboratories' operations span APIs, medical devices, and finished formulations. The company is a global exporter of six major APIs, including Loratadine, Montelukast, Desloratadine, Atorvastatin, and Fexofenadine. In the medical devices segment, Morepen has installed over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips, supporting its expansion into tier-2 and tier-3 cities.

The company's consolidated net profit fell 16.6% to Rs 26.69 crore while revenue from operations rose 1.9% to Rs 452.78 crore in Q3 December 2024 over Q3 December 2023.

Powered by Capital Market - Live News

Morepen Laboratories today announced a bold expansion plan aimed at deepening its connect with doctors, patients, pharmacies, and healthcare professionals across the country. As part of this strategic initiative, the company will add more than 1,000 professionals to its salesforce over the next three years, with over 200 team members expected to join in FY26 alone.

This expansion represents a pivotal moment in Morepen's journey as we sharpen our focus on the expanding domes c finished dosage market, said Sushil Suri, Chairman and Managing Director of Morepen Laboratories. With the leadership in our high value APIs, this significant increase in our salesforce and enhanced reach to doctors, pharmacies, and patients, we are se ng the stage for getting a bigger pie in the Indian pharmaceutical market valued at ₹2.38 lakh crore, yielding higher gross margins and be er returns for stakeholders in the long run.?

Powered by Capital Market - Live News